On a consolidated basis, the drug maker's net profit jumped 27% to Rs 310 crore on 0.9% increase in net sales to Rs 1,985 crore in Q2 September 2020 over Q2 September 2019.
Profit before tax (PBT) soared 29.7% to Rs 384 crore in Q2 September 2020 as against Rs 296 crore in Q2 September 2019. Total tax expense for the quarter rose 42.31% to Rs 74 crore as against Rs 52 crore in Q2 September 2019. The Q2 result was declared after trading hours yesterday, 26 October 2020.
EBITDA galloped 12% to Rs 641 crore in Q2 FY21 as against Rs 573 crore in Q2 FY20, driven by recovery in India and productivity gains. EBITDA margin improved to 32% in Q2 FY21 from 12% in Q2 FY20.
Gross profit fell marginally 0.27% to Rs 1,463 crore (margins at 73%) in Q2 FY21 as against Rs 1,467 crore (margins at 73%) in Q2 FY20. Research & Development (R&D) spend slipped 8% to Rs 119 crore in Q2 FY21 as against Rs 130 crore in Q2 FY20.
In India, the sub-chronic and acute segments witnessed gradual recovery during the quarter while chronic momentum continued. Field Force productivity (PCPM) for the quarter stood at Rs 8 lakh with an MR strength of 4,000.
Globally, US revenues declined 14% Y-o-Y (year-on-year) to Rs 327 crore in Q2 FY21, Brazil revenues skid 18% Y-o-Y to Rs 129 crore in Q2 FY21 while Germany revenues advanced 4% Y-o-Y to Rs 261 crore in Q2 September 2020.
Shares of Torrent Pharmaceuticals declined 2.84% to Rs 2,579 on BSE. Torrent Pharmaceuticals, is the flagship company of the Torrent Group. Torrent Pharma is amongst the top 5 in the therapeutics segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro intestinal (GI), and Vitamins Minerals Nutritionals (VMN).
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU